Market Cap 88.09M
Revenue (ttm) 0.00
Net Income (ttm) -56.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.45
Volume 689,800
Avg Vol 199,990
Day's Range N/A - N/A
Shares Out 53.71M
Stochastic %K 64%
Beta 1.07
Analysts Strong Sell
Price Target $7.40

Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an aut...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 910 5717
Address:
611 Gateway Boulevard, Suite 273, South San Francisco, United States
ADSlay
ADSlay Oct. 3 at 1:34 AM
$QNCX Did anyone else notice how clinically precise the handover was between every speaker? — tells a lot about Managements - this one runs a tight ship! Makes helluva difference in biotech world. After watching the no-nonsense Quince Investor's Virtual Conference Day today, I am more convinced this Management will get us home, imo. Alzheimer's was a very tough disease, this one has a light at the end of the tunnel, and it's a bright one! Their collective experience stood out for me personally.
0 · Reply
ADSlay
ADSlay Oct. 2 at 6:02 PM
$QNCX Here's the deck presented today, lot of good, concrete and objective information: https://ir.quincetx.com/news-and-events/presentations
0 · Reply
ADSlay
ADSlay Oct. 2 at 4:06 PM
$QNCX It was a great session. Money slide here; it is not just BioX talking about Reata-Biogen but $QNCX Management knows this is their baseline. We will see. Watching the team together made me even more confident. But that is just me, DYODD.
0 · Reply
QNCXtothemoon
QNCXtothemoon Oct. 2 at 3:58 PM
$QNCX https://www.youtube.com/watch?v=n0UYTi_3tAw
0 · Reply
dv1809
dv1809 Oct. 2 at 12:18 PM
0 · Reply
MorenitaScorp
MorenitaScorp Oct. 1 at 8:14 PM
$QNCX ⌚️
0 · Reply
highnihilism
highnihilism Oct. 1 at 12:03 PM
$VTIP Short-Term Inflation-Protected Securities ETF Trades: 6 | Total $: 493 | 0.25 × 90-Day Avg $: 2 K | Call $: 493 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $IVW iShares S&P 500 Growth ETF Trades: 6 | Total $: 934 | 0.01 × 90-Day Avg $: 83.9 K | Call $: 493 | Put $: 441 | Single-Leg: 67% | Multi-Leg: 33% | Contingent: – $SLX Vaneck Steel ETF Trades: 1 | Total $: 492 | 0.18 × 90-Day Avg $: 2.7 K | Call $: 492 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $QNCX Quince Therapeutics Trades: 2 | Total $: 481 | 0.10 × 90-Day Avg $: 4.9 K | Call $: 481 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
WycklyTrader
WycklyTrader Sep. 26 at 9:52 PM
$QNCX potential breakout with upcoming FDA catalyst. $NIO $GME $PLUG : $GRAB some shAIRS.
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 26 at 11:29 AM
$QNCX D. Boral Capital Maintains Buy on Quince Therapeutics, Maintains $4 Price Target
0 · Reply
JarvisFlow
JarvisFlow Sep. 26 at 11:27 AM
D. Boral Capital has adjusted their stance on Quince Therapeutics ( $QNCX ), setting the rating to Buy with a target price of 4.
0 · Reply
Latest News on QNCX
Quince Therapeutics, Inc. - Special Call

Sep 24, 2025, 1:13 AM EDT - 10 days ago

Quince Therapeutics, Inc. - Special Call


Quince Therapeutics Launches Scientific Advisory Board

Feb 22, 2024, 7:00 AM EST - 1 year ago

Quince Therapeutics Launches Scientific Advisory Board


Quince Therapeutics Completes Acquisition of EryDel S.p.A.

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Completes Acquisition of EryDel S.p.A.


Quince Therapeutics Appoints Dr. Charles S. Ryan as President

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Appoints Dr. Charles S. Ryan as President


ADSlay
ADSlay Oct. 3 at 1:34 AM
$QNCX Did anyone else notice how clinically precise the handover was between every speaker? — tells a lot about Managements - this one runs a tight ship! Makes helluva difference in biotech world. After watching the no-nonsense Quince Investor's Virtual Conference Day today, I am more convinced this Management will get us home, imo. Alzheimer's was a very tough disease, this one has a light at the end of the tunnel, and it's a bright one! Their collective experience stood out for me personally.
0 · Reply
ADSlay
ADSlay Oct. 2 at 6:02 PM
$QNCX Here's the deck presented today, lot of good, concrete and objective information: https://ir.quincetx.com/news-and-events/presentations
0 · Reply
ADSlay
ADSlay Oct. 2 at 4:06 PM
$QNCX It was a great session. Money slide here; it is not just BioX talking about Reata-Biogen but $QNCX Management knows this is their baseline. We will see. Watching the team together made me even more confident. But that is just me, DYODD.
0 · Reply
QNCXtothemoon
QNCXtothemoon Oct. 2 at 3:58 PM
$QNCX https://www.youtube.com/watch?v=n0UYTi_3tAw
0 · Reply
dv1809
dv1809 Oct. 2 at 12:18 PM
0 · Reply
MorenitaScorp
MorenitaScorp Oct. 1 at 8:14 PM
$QNCX ⌚️
0 · Reply
highnihilism
highnihilism Oct. 1 at 12:03 PM
$VTIP Short-Term Inflation-Protected Securities ETF Trades: 6 | Total $: 493 | 0.25 × 90-Day Avg $: 2 K | Call $: 493 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $IVW iShares S&P 500 Growth ETF Trades: 6 | Total $: 934 | 0.01 × 90-Day Avg $: 83.9 K | Call $: 493 | Put $: 441 | Single-Leg: 67% | Multi-Leg: 33% | Contingent: – $SLX Vaneck Steel ETF Trades: 1 | Total $: 492 | 0.18 × 90-Day Avg $: 2.7 K | Call $: 492 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $QNCX Quince Therapeutics Trades: 2 | Total $: 481 | 0.10 × 90-Day Avg $: 4.9 K | Call $: 481 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
WycklyTrader
WycklyTrader Sep. 26 at 9:52 PM
$QNCX potential breakout with upcoming FDA catalyst. $NIO $GME $PLUG : $GRAB some shAIRS.
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 26 at 11:29 AM
$QNCX D. Boral Capital Maintains Buy on Quince Therapeutics, Maintains $4 Price Target
0 · Reply
JarvisFlow
JarvisFlow Sep. 26 at 11:27 AM
D. Boral Capital has adjusted their stance on Quince Therapeutics ( $QNCX ), setting the rating to Buy with a target price of 4.
0 · Reply
QNCXtothemoon
QNCXtothemoon Sep. 25 at 8:51 PM
$QNCX https://ir.quincetx.com/news-releases/news-release-details/quince-therapeutics-announces-cpt-pharmacometrics-systems
0 · Reply
iAm_Goatz
iAm_Goatz Sep. 18 at 7:35 PM
$QNCX Ready for the 10/2 investor event! ✅🫡⚡️🦍🦍🦍 https://register.quincetx.com/investorday
0 · Reply
kb60521
kb60521 Sep. 17 at 9:53 PM
$QNCX Anyone here who have seen double digit price? what are your latest thoughts??? Please share....
1 · Reply
FrackMaster
FrackMaster Sep. 17 at 3:37 PM
0 · Reply
FrackMaster
FrackMaster Sep. 17 at 3:37 PM
If $QNCX even sniffs positive data or a partner deal, it's lights out. 🚀
0 · Reply
dv1809
dv1809 Sep. 17 at 1:17 PM
$QNCX 3 usd in 3 months 😎
0 · Reply
kb60521
kb60521 Sep. 16 at 12:16 PM
$QNCX Still anyone there hoping for a patch up in this marriage ? :)
0 · Reply
RD008
RD008 Sep. 12 at 2:23 PM
0 · Reply
4o1k
4o1k Sep. 9 at 7:52 PM
0 · Reply
QNCXtothemoon
QNCXtothemoon Sep. 5 at 1:50 PM
$QNCX https://ir.quincetx.com/static-files/e8cd872c-ad31-4bf5-a1a4-7fdd79e0b421
0 · Reply
QNCXtothemoon
QNCXtothemoon Sep. 5 at 1:33 PM
$QNCX https://ir.quincetx.com/static-files/e8cd872c-ad31-4bf5-a1a4-7fdd79e0b421
0 · Reply
4o1k
4o1k Sep. 3 at 5:44 PM
$QNCX The time is near.
0 · Reply